Sam Brusco, Associate Editor02.22.22
Smith+Nephew has appointed Dr. Deepak Nath as its new CEO. He succeeds Roland Digglemann, who reportedly stepped down by mutual agreement. Dr. Nath will begin leading the company on April 1.
Dr. Nath was most recently president of Diagnostics as Siemens Healthineers. Before that he held senior positions at Abbott Labs, rising to become president of Abbott Vascular. He had a leadership role in the $28 billion deal for St. Jude Medical.
He also worked for Amgen, McKinsey and Company, and as a scientist at the Lawrence Livermore National Laboratory. Dr. Nath has BSc and MSc degrees from the University of California, Berkeley.
“On behalf of the Board, I am delighted to welcome Deepak as Smith+Nephew’s incoming CEO,” Smith+Nephew Chairman Roberto Quarta told the press. “Deepak is a highly experienced leader with a track record of significant improvement in operations and execution at major global healthcare businesses. He is joining us at an inflection point for the business and will bring his drive, experience and expertise to lead the team in delivering our Strategy for Growth at pace. I would like to thank Roland for his commitment and leadership during challenging times, and the important work he has done to ready Smith+Nephew for our next stage of development.”
“Smith+Nephew is a great company with innovation at its core and a purpose of Life Unlimited, supporting patients around the world in returning to a healthy and fulfilled life,” said Dr. Nath. “I am honoured to have been given the opportunity to lead the business. I look forward to building on Smith+Nephew’s rich history and heritage and working with the team to take it to the next level of growth.”
“It has been a privilege to lead Smith+Nephew,” said Diggelmann. “I would like to thank my colleagues across the business for their tireless efforts to support our customers and communities, and continue to deliver against the backdrop of COVID. I look forward to seeing the business go from strength to strength under Deepak’s leadership.”
Dr. Nath was most recently president of Diagnostics as Siemens Healthineers. Before that he held senior positions at Abbott Labs, rising to become president of Abbott Vascular. He had a leadership role in the $28 billion deal for St. Jude Medical.
He also worked for Amgen, McKinsey and Company, and as a scientist at the Lawrence Livermore National Laboratory. Dr. Nath has BSc and MSc degrees from the University of California, Berkeley.
“On behalf of the Board, I am delighted to welcome Deepak as Smith+Nephew’s incoming CEO,” Smith+Nephew Chairman Roberto Quarta told the press. “Deepak is a highly experienced leader with a track record of significant improvement in operations and execution at major global healthcare businesses. He is joining us at an inflection point for the business and will bring his drive, experience and expertise to lead the team in delivering our Strategy for Growth at pace. I would like to thank Roland for his commitment and leadership during challenging times, and the important work he has done to ready Smith+Nephew for our next stage of development.”
“Smith+Nephew is a great company with innovation at its core and a purpose of Life Unlimited, supporting patients around the world in returning to a healthy and fulfilled life,” said Dr. Nath. “I am honoured to have been given the opportunity to lead the business. I look forward to building on Smith+Nephew’s rich history and heritage and working with the team to take it to the next level of growth.”
“It has been a privilege to lead Smith+Nephew,” said Diggelmann. “I would like to thank my colleagues across the business for their tireless efforts to support our customers and communities, and continue to deliver against the backdrop of COVID. I look forward to seeing the business go from strength to strength under Deepak’s leadership.”